News & Media
Newsroom
SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia
5.20.2020
Full Release
SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults
5.11.2020
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate fact sheet
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 8 compounds under clinical development